

## Casgevy™ (exagamglogene autotemcel) (Intravenous)

Effective Date: 05/01/2024

Review Date: 03/20/2024, 10/09/2024

Scope: Medicaid, Commercial, Medicare-Medicaid Plan (MMP)

### I. Length of Authorization

Coverage will be provided for one treatment course (1 dose of Casgevy) and may not be renewed.

### II. Dosing Limits

#### A. Quantity Limit (max daily dose) [NDC Unit]:

- A single dose of Casgevy containing a minimum of  $3.0 \times 10^6$  CD34+ cells/kg of body weight, in multiple vials

#### B. Max Units (per dose and over time) [HCPS Unit]:

- A single dose of Casgevy containing a minimum of  $3.0 \times 10^6$  CD34+ cells/kg of body weight, in multiple vials

### III. Summary of Evidence:

Casgevy (exagamglogene autotemcel) is indicated for the treatment of sickle cell disease (SCD) in patients 12 years and older with recurrent vaso-occlusive crises (VOCs). Casgevy was evaluated in an ongoing single-arm, multicenter, phase 1/2/3 trial with patients who had a history of at least 2 protocol-defined severe VOC events during each of the 2 years prior to screening. Of the 63 patients enrolled in the trial, 44 patients went on to receive Casgevy to form the full analysis set (FAS). Of the 44 patients from the FAS, 31 had adequate follow-up to allow evaluation of the primary efficacy endpoint and formed the primary efficacy set (PES). The primary efficacy outcome was the proportion of VF12 responders, defined as patients who did not experience any protocol-defined severe VOCs for at least 12 consecutive months within the first 24 months after treatment with Casgevy. The VF12 response rate was 29/31 (93.5%, 98% one-sided CI: 77.9%, 100.0%). The proportion of patients who did not require hospitalization due to severe VOCs for at least 12 consecutive months within the 24-month evaluation period (HF12) was also assessed. One patient was not evaluable for HF12 response; the remaining 30 patients achieved the endpoint of HF12 (100% [98% one-sided CI: 87.8%, 100.0%]). The most common grade 3 or 4 adverse reactions with an incidence  $\geq 25\%$  were mucositis, febrile neutropenia, and decreased appetite. The most common grade 3 or 4 laboratory abnormalities ( $\geq 50\%$ ) were neutropenia, thrombocytopenia, leukopenia, anemia, and lymphopenia.

## IV. Initial Approval Criteria <sup>1</sup>

Submission of medical records (chart notes) related to the medical necessity criteria is **REQUIRED** on all requests for authorizations. Records will be reviewed at the time of submission. Please provide documentation related to diagnosis, step therapy, and clinical markers (i.e. genetic and mutational testing) supporting initiation when applicable. Please provide documentation via direct upload through the PA web portal or by fax.

Coverage is provided in the following conditions:

- Patient is at least 12-35 years of age; **AND**
- Provider has considered use of prophylaxis therapy for seizures prior to initiating myeloablative conditioning; **AND**
- Patient has been screened and found negative for hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus 1 & 2 (HIV-1/HIV-2) in accordance with clinical guidelines prior to collection of cells (leukapheresis); **AND**
- Must not be administered concurrently with live vaccines while immunosuppressed; **AND**
- Patient does not have a history of hypersensitivity to dimethyl sulfoxide (DMSO) or dextran 40; **AND**
- Patient has not received other gene therapies [e.g., Lyfgenia® (lovotibeglogene autotemcel), Zynteglo® (betibeglogene autotemcel), etc]; **AND**
- Patient will not receive therapy concomitantly with any of the following:
  - Iron chelators for 7-days prior to mobilization and 6 months post-treatment (3-months post-treatment for non-myelosuppressive iron chelators); **AND**
  - Disease-modifying agents (e.g., hydroxyurea or Adakveo (crizanlizumab) for at least 8-weeks prior to mobilization and conditioning; **AND**
- Patient does not have a known 10/10 human leukocyte antigen matched related donor willing to participate in an allogeneic HSCT; **AND**
- Patient is a candidate for autologous hematopoietic stem cell transplant (HSCT) [i.e., patient does not have deficiencies in bone marrow, lung, heart, or liver function]; **AND**
- Patient does not have a history of previous hematopoietic stem cell transplant (HCST); **AND**
- Patient does not have a potential contraindication to any product or procedure required for successful gene therapy treatment including (but not limited to):
  - Plerixafor; **AND**
  - Busulfan; **AND**
  - Red blood cell infusion; **AND**
- Patient will undergo treatment at a manufacturer approved Authorized Treatment Center (ATC); **AND**
- Casgevy is prescribed by, or in consultation with, a specialist in hematology; **AND**

### Sickle Cell Disease † Φ

- Patient has a confirmed diagnosis of sickle-cell disease (includes genotypes  $\beta^S/\beta^S$  or  $\beta^S/\beta^0$  or  $\beta^S/\beta^+$ ) as determined by one of the following:
  - Identification of significant quantities of HbS with or without an additional abnormal  $\beta$ -globin chain variant by hemoglobin assay; **OR**

- Identification of biallelic *HBB* pathogenic variants where at least one allele is the p.Glu6Val pathogenic variant on molecular genetic testing; **AND**
- Patient has symptomatic disease despite treatment with hydroxyurea and formulary add-on therapy (e.g., Adakveo (crizanlizumab), etc.); **AND**
- Patient experienced two or more vaso-occlusive event/crises (VOE/VOC)\* per year in the previous two years while adhering to the above therapy; **AND**
- Patient will be transfused prior to apheresis to a total Hb  $\leq$  11 g/dL and a HbS level  $<$ 30% and patient will be transfused at least 8 weeks prior to initiation of myeloablative conditioning (with aforementioned Hb and HbS goals); **AND**
- Patient will not receive granulocyte-colony stimulating factor (G-CSF) for the mobilization of hematopoietic stem cells (HSC)

*\*VOE/VOC is defined as an event requiring a visit to a medical facility for evaluation which results in a diagnosis of such being documented due to one (or more) of the following: acute pain, acute chest syndrome, acute splenic sequestration, acute hepatic sequestration, priapism lasting > 2 hours AND necessitating subsequent interventions such as opioid pain management, non-steroidal anti-inflammatory drugs, RBC transfusion, etc.*

### **Beta Thalassemia †<sup>1,10,12</sup>**

- Patient has a documented diagnosis of homozygous beta thalassemia or compound heterozygous beta thalassemia including  $\beta$ -thalassemia/hemoglobin E (HbE) as outlined by the following:
  - Patient diagnosis is confirmed by *HBB* sequence gene analysis showing biallelic pathogenic variants; OR
  - Patient has severe microcytic hypochromic anemia, absence of iron deficiency, anisopoikilocytosis with nucleated red blood cells on peripheral blood smear, and hemoglobin analysis that reveals decreased amounts or complete absence of hemoglobin A (HbA) and increased HbA2 with or without increased amounts of hemoglobin F (HbF); **AND**
- Patient has transfusion-dependent disease defined as a history of transfusions of at least 100 mL/kg/year or  $\geq$ 10 units/year of packed red blood cells (pRBCs) in the 2 years preceding therapy; **AND**
- Patient will be transfused prior to apheresis to a total Hb  $\geq$  11 g/dL for 60 days prior to myeloablative conditioning; **AND**
- Patient does not have any of the following:
  - Severely elevated iron in the heart (i.e., patients with cardiac T2\* less than 10 msec by magnetic resonance imaging [MRI] or left ventricular ejection fraction [LVEF]  $<$  45% by echocardiogram); OR
  - Advanced liver disease [i.e., AST or ALT  $>$  3 times the upper limit of normal (ULN), or direct bilirubin value  $>$  2.5 times the ULN, or if a liver biopsy demonstrated bridging fibrosis or cirrhosis]

MMP members who have previously received this medication within the past 365 days are not subject to Step Therapy Requirements.

† FDA Approved Indication(s); ‡ Compendia Recommended Indication(s); Ⓢ Orphan Drug

## V. Renewal Criteria <sup>1,3</sup>

- Coverage cannot be renewed.

## VI. Dosage/Administration <sup>1</sup>

Indication	Dose
Sickle-Cell Disease or Beta Thalassemia	Casgevy is provided as a single dose for intravenous infusion containing a suspension of CD34+ cells in one or more vials to achieve the patient-specific dose. Administer all vials. <ul style="list-style-type: none"><li>• The minimum recommended dose of Casgevy is <math>3 \times 10^6</math> CD34+ cells/kg.</li></ul>
<i>- Sickle Cell Disease: Mobilization should occur using single agent plerixafor</i>	
<i>- Beta Thalassemia: Mobilization should occur using both plerixafor and Granulocyte-Colony Stimulating Factor (G-CSF)</i>	
<i>- Myeloablative conditioning (e.g., busulfan) should not occur until Casgevy (and back-up cell collection) are received. Prophylaxis for hepatic veno-occlusive disease (VOD)/ hepatic sinusoidal obstruction syndrome should be considered.</i>	
<i>- Casgevy must be administered between 48 hours and 7 days after the last dose of the myeloablative conditioning.</i>	
<i>- Casgevy is for autologous use only. Before infusion, confirm that the patient's identity matches the unique patient identifiers on the Casgevy vial(s). Do not infuse if the information on the patient-specific label does not match the intended patient.</i>	

## VII. Billing Code/Availability Information

### HCPCS:

- J3590 – Unclassified biologics

### NDC:

- Casgevy containing a minimum of  $3.0 \times 10^6$  CD34+ cells/kg of body weight, in multiple vials supplied in vial(s) packaged in carton(s): 51167-0290-xx

## VIII. References

1. Casgevy [package insert]. Boston, MA; Vertex, Inc., January 2024. Accessed March 2024.
2. Frangoul H, Altshuler D, Cappellini D, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and  $\beta$ -Thalassemia. Jan 21, 2021 N Engl J Med 2021; 384:252-260 DOI: 10.1056/NEJMoa2031054.
3. Bender MA, Carlberg K. Sickle Cell Disease. 2003 Sep 15 [Updated 2022 Nov 17]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1377/>.
4. Yawn BP, Buchanan GR, Afenyi-Annan AN, et al. Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. JAMA. 2014 Sep 10;312(10):1033-48.
5. Tisdale JF, Pierciey FJ, Bonner M, et al. (2020) Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. Am J Hematol E239–E242. <https://doi.org/10.1002/ajh.25867>.
6. Palmer J, McCune JS, Perales M-A, et al. (2016) Personalizing Busulfan-Based Conditioning: Considerations from the American Society for Blood and Marrow Transplantation Practice Guidelines Committee. Biol Blood Marrow Transplant 1915–1925. <https://doi.org/10.1016/j.bbmt.2016.07.013>
7. Brunson A, Keegan THM, Bang H, et al. (2017) Increased risk of leukemia among sickle cell disease patients in California. Blood 130:1597–1599. doi: 10.1182/blood-2017-05-783233.

8. Seminog OO, Ogunlaja OI, Yeates D, Goldacre MJ (2016) Risk of individual malignant neoplasms in patients with sickle cell disease: English national record linkage study. *J R Soc Med* 109:303–309. doi: 10.1177/0141076816651037.
9. Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. *Prog Mol Biol Transl Sci*. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.
10. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and beta-Thalassemia. *N Engl J Med*. 2021 Jan 21;384(3):252-260. doi: 10.1056/NEJMoa2031054. Epub 2020 Dec 5.
11. Modarai SR, Kanda S, Bloh K, et al. Precise and error-prone CRISPR-directed gene editing activity in human CD34+ cells varies widely among patient samples. *Gene Ther*. 2021 Feb;28(1-2):105-113. doi: 10.1038/s41434-020-00192-z. Epub 2020 Sep 1.

## Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D57.00	Hb-SS disease with crisis unspecified
D57.01	Hb-SS disease with acute chest syndrome
D57.02	Hb-SS disease with splenic sequestration
D57.03	Hb-SS disease with cerebral vascular involvement
D57.04	Hb-SS disease with crisis with other specified complication
D57.1	Sickle-cell disease without crisis
D57.20	Sickle-cell/Hb-C disease without crisis
D57.211	Sickle-cell/Hb-C disease with acute chest syndrome
D57.212	Sickle-cell/Hb-C disease with splenic sequestration
D57.213	Sickle-cell/Hb-C disease with cerebral vascular involvement
D57.214	Sickle-cell/Hb-C disease with crisis with other specified complication
D57.219	Sickle-cell/Hb-C disease with crisis unspecified
D57.3	Sickle-cell trait
D57.40	Sickle-cell thalassemia without crisis
D57.411	Sickle-cell thalassemia with acute chest syndrome
D57.412	Sickle-cell thalassemia with splenic sequestration
D57.413	Sickle-cell thalassemia, unspecified, with cerebral vascular involvement
D57.414	Sickle-cell thalassemia, unspecified, with crisis with other specified complication
D57.419	Sickle-cell thalassemia with crisis unspecified
D47.42	Sickle-cell thalassemia beta zero without crisis
D57.431	Sickle-cell thalassemia beta zero with acute chest syndrome
D57.432	Sickle-cell thalassemia beta zero with splenic sequestration
D57.433	Sickle-cell thalassemia beta zero with cerebral vascular involvement
D57.434	Sickle-cell thalassemia beta zero with crisis with other specified complication
D57.439	Sickle-cell thalassemia beta zero with crisis unspecified
D57.44	Sickle-cell thalassemia beta plus without crisis
D57.451	Sickle-cell thalassemia beta plus with acute chest syndrome
D57.452	Sickle-cell thalassemia beta plus with splenic sequestration

D57.453	Sickle-cell thalassemia beta plus with cerebral vascular involvement
D57.454	Sickle-cell thalassemia beta plus with crisis with other specified complication
D57.459	Sickle-cell thalassemia beta plus with crisis unspecified
D57.80	Other sickle-cell disorders without crisis
D57.811	Other sickle-cell disorders with acute chest syndrome
D57.812	Other sickle-cell disorders with splenic sequestration
D57.813	Other sickle-cell disorders with cerebral vascular involvement
D57.814	Other sickle-cell disorders with crisis with other specified complication
D57.819	Other sickle-cell disorders with crisis, unspecified

## Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations (NCDs) and/or Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. Local Coverage Articles (LCAs) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT, AZ	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in VA)	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC

### Policy Rationale:

Casgevay was reviewed by the Neighborhood Health Plan of Rhode Island Pharmacy & Therapeutics (P&T) Committee. Neighborhood adopted the following clinical coverage criteria to ensure that its members use Casgevay according to Food and Drug Administration (FDA) approved labeling and/or relevant clinical literature. Neighborhood worked with network prescribers and pharmacists to draft these criteria. These criteria will help ensure

its members are using this drug for a medically accepted indication, while minimizing the risk for adverse effects and ensuring more cost-effective options are used first, if applicable and appropriate. For INTEGRITY (Medicare-Medicaid Plan) members, these coverage criteria will only apply in the absence of National Coverage Determination (NCD) or Local Coverage Determination (LCD) criteria. Neighborhood will give individual consideration to each request it reviews based on the information submitted by the prescriber and other information available to the plan.